NEWS
Evonik manufactures first rhamnolipids from Slovakia plant
Evonik has kicked off rhamnolipids production ahead of schedule at its industrial-scale biosurfactants plant in Slovakia. The Slovenská Ľupča facility,
which deploys a fermentation- based manufacturing process, is the first worldwide to produce sustainable rhamnolipid biosurfactants. Rhamnolipids are a class of
biosurfactants that are sustainably manufactured using European corn sugar as the main raw material. This biogenic, carbon-
based process does not require petrochemical feedstocks or tropical oils. Rhamnolipids are fully
biodegradable and offer a sustainable alternative to conventional surfactants due
to their biobased raw materials, and low toxicological and ecotoxicological profile. “Our high-performance
rhamnolipids are setting a precedent, not only at Evonik, but as part of a broader sustainable chemicals revolution. We are excited to be leading the way with our biosolutions,” said Johann-Caspar Gammelin, president of Evonik’s Nutrition & Care division. “Completing this plant ahead
of schedule is a milestone for our business and a testament to our technical expertise, but most importantly, it enables our customers to bring more sustainable cleaning and personal care products to market faster,” added Yann d’Hervé, head of Evonik’s Care Solutions business line.
The speciality chemicals,
mainly surfactants, produced in the newly certified Essen Goldschmidt site are often used for cleansing, foaming, emulsifying and solubilizing purposes. They will include TEGOSTAB
In a related development,
Evonik has attained the International Sustainability and Carbon Certification (ISCC) PLUS for its speciality chemicals production site in Essen, Germany. The certification is based on the mass balance approach, which ensures that sustainable feedstocks are used and that the supply chain is traceable.
additives for polyurethane foams for mattresses or insulation panels, TEGO industrial coatings and inks, TEGOMER, TAGAT and TEGO PE for industrial processes and further applications in agrochemistry and personal care. Starting in the first half of
this year, existing and new customers will have access to these certified surfactants containing a significant amount of mass balanced feedstock, and consequently a lower carbon footprint.
Solvay spin-off Syensqo invests in Argentina’s Bioeutectics
Solvay spin-off Syensqo has participated in a $2.1 million financing round for Argentinian biotech startup Bioeutectics, which makes green solvents. Founded in 2019,
Bioeutectics provides natural and high-performance solvents that make industrial products and processes more sustainable. Based on pioneering
technology - Natural Deep Eutectic Solvents (NADES) - Bioeutetics mimics the way plants elaborate their own solvents
using 100% renewable sources. By replacing petrochemical-
based solvents with natural alternatives, the Mendoza-based outfit provides solvents with an improved environmental, health, and safety profile that are aligned with and contribute to the achievement of sustainable development goals. “We see a growing demand
for efficient and environmentally friendly solvents, which can also be biodegradable, non-toxic and affordable,” said Jean-Christophe
sustainability that could bring real added value to Syensqo’s portfolio of products,” he added. Syensqo, which was spun off
Castaing, Global R&I Director, New Technologies at Syensqo. “Bioeutetics’ cutting-edge
technology is at the forefront of solvent innovation, combining high-performance, quality and
from Solvay in December, made the investment via its venture capital fund alongside Fen Ventures, Atento Capital and SOSV (IndieBio). The investment strengthens
the existing partnership between Syensqo Ventures and the Genesis Consortium, supporting startups in the SOSV’s IndieBio startup development programme, it said.
IMCD expands India presence with Valuetree buy
Speciality ingredient distributor IMCD has acquired a majority stake in Valuetree Ingredients to expand its beauty and personal care footprint in India. Founded in 2005, Valuetree
employs a team of 44 staff and generated revenue of approximately 4.4 billion rupees (circa €48m) in the financial year ending 31 March 2023. The transaction will take
place in two tranches, with IMCD initially acquiring 70% of the share
www.personalcaremagazine.com
capital and the remaining 30% to be acquired next year. Valuetree is an ingredient
supplier to the beauty and personal care market that provides an extensive portfolio to its customers through an in-house application laboratory with formulation and technical support. The founders, Shailesh Karwa
and Sharad Dalmia, will continue to lead the company post- completion of this first tranche.
“In a market dominated by
large players, and now witnessing the emergence of direct to consumer (D2C) brands, our focus has been on customer centricity and providing innovative solutions. We are delighted that IMCD has partnered with us in Valuetree’s next phase of growth,” they
said.IMCD India & Bangladesh managing director Narendra Varde added: “As the beauty and personal care market in India continues to experience
9
double-digit growth, acquiring Valuetree perfectly fits in our global strategy, it significantly enhances our capabilities and enriches our product portfolio.”
March 2024 PERSONAL CARE
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112
